Single-center analysis of a real-world cohort of patients with metastatic urothelial carcinoma evaluated by NGS: molecular landscape and efficacy of targeted therapies-Reference-Cited by-同舟云学术

Single-center analysis of a real-world cohort of patients with metastatic urothelial carcinoma evaluated by NGS: molecular landscape and efficacy of targeted therapies

Published:2024-08-15 Issue: Volume: Page:
ISSN:1699-3055
Container-title:Clinical and Translational Oncology
language:en
Short-container-title:Clin Transl Oncol

Author:

Gutiérrez Pérez César^ORCID,Lastra Aras Enrique,Saiz López Patricia,García Toro Enrique,Blanco Abad Carmen,Rodríguez Ledesma Inmaculada,Pumares González María,Vela Domínguez Miriam,Espinosa Cabria Noelia,Crespo Herrero Guillermo

Funder

AstraZeneca España

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12094-024-03651-w.pdf

Reference30 articles.

1. Valderrama BP, González-Del-Alba A, Morales-Barrera R, Fernández IP, Vázquez S, Díaz CC, et al. SEOM-SOGUG clinical guideline for localized muscle invasive and advanced bladder cancer (2021). Clin Transl Oncol. 2022;24:613–24. https://doi.org/10.1007/s12094-022-02815-w.

2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660.

3. Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383:1218–30. https://doi.org/10.1056/NEJMoa2002788.

4. Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ, et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of > 2 years of follow-up. Ann Oncol. 2019;30:970–6. https://doi.org/10.1093/annonc/mdz127.

5. Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Durán I, Lee JL, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384:1125–35. https://doi.org/10.1056/NEJMoa2035807.